The compounded vs brand-name decision is the most consequential choice you'll make when starting GLP-1 medication. Both options use the same active ingredients, but they differ in FDA status, cost, manufacturing, and availability. Here's how to decide.
The Core Differences
| Factor | Compounded GLP-1 | Brand-Name GLP-1 |
|---|---|---|
| FDA Status | Not FDA-approved as finished product | FDA-approved |
| Active Ingredient | Same (semaglutide or tirzepatide) | Same |
| Manufacturing | 503A/503B compounding pharmacy | Novo Nordisk / Eli Lilly |
| Monthly Cost (self-pay) | $99–$279/mo | $997–$1,349/mo (list price) |
| Insurance Coverage | Not covered | Possible (30-60% initial denial rate) |
| Clinical Trial Data | Based on brand-name trials (same ingredient) | Direct clinical trial data |
| Regulatory Risk | FDA 503B exclusion proposed | Stable |
When Compounded Makes Sense
Compounded GLP-1s are appropriate for most patients who are self-paying and don't have insurance coverage for brand-name versions. The active ingredient is identical, the medications are prepared in FDA-registered pharmacies, and millions of patients use them safely. At 60–80% lower cost, the financial advantage is significant — especially for a medication you may take for years.
Sunlight $159/mo sema, $239/mo tirz · LegitScript certified. Flat pricing — $159 first month, $179 ongoing (semaglutide). No membership, free shipping, HSA/FSA.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Oak Longevity $130/mo flat · One of the lowest flat-rate prices available. $130/mo semaglutide, $199/mo tirzepatide at any dose. Free coaching.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
When Brand-Name Makes Sense
Brand-name GLP-1s are the better choice if you have insurance coverage that pays for them, you want the exact formulation used in clinical trials, you have concerns about compounding pharmacy quality, or you're eligible for the Medicare GLP-1 Bridge ($50/month starting July 1, 2026).
Sesame Care From $99/visit · Prescribes FDA-approved brand-name medications only. Accepts insurance. No subscription lock-in.
Prescribes FDA-approved brand-name medications only.
Regulatory watch: The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The comment period closes June 29, 2026. If finalized, this would significantly impact compounded GLP-1 availability from large-scale compounders. Current patients should monitor this situation but are not immediately affected.